4//SEC Filing
Doyle Ramona 4
Accession 0001209191-22-007915
CIK 0001601830other
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 9:09 PM ET
Size
14.3 KB
Accession
0001209191-22-007915
Insider Transaction Report
Form 4
Doyle Ramona
Chief Medical Officer
Transactions
- Award
Class A Common Stock
2022-02-04+38,499→ 95,834 total - Award
Class A Common Stock
2022-02-04+2,392→ 98,226 total - Tax Payment
Class A Common Stock
2022-02-04$11.40/sh−981$11,183→ 97,245 total - Award
Stock Option (Right to Buy)
2022-02-04+76,998→ 76,998 totalExercise: $11.40Exp: 2032-02-04→ Class A Common Stock (76,998 underlying) - Award
Stock Option (Right to Buy)
2022-02-04+4,784→ 4,784 totalExercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (4,784 underlying)
Holdings
- 694,053
Stock Option (Right to Buy)
Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (694,053 underlying)
Footnotes (4)
- [F1]This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter.
- [F2]This RSU vested immediately upon the grant date.
- [F3]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F4]Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0001856069
Filing Metadata
- Form type
- 4
- Filed
- Feb 7, 7:00 PM ET
- Accepted
- Feb 8, 9:09 PM ET
- Size
- 14.3 KB